PORTSMOUTH, N.H., March 17, 2021 /PRNewswire/ -- Epredia, a
global leader in precision cancer diagnostics, and Paige, a global
leader in AI-based diagnostic software in pathology, have announced
today that they have entered into a commercial distribution
agreement for Paige's comprehensive portfolio of diagnostic
software solutions.
Under the terms of this agreement, Epredia has been appointed as
a global distribution partner of the entire Paige portfolio of
imaging diagnostic solutions. In addition, Epredia will have
exclusive distribution rights in Japan. In the second quarter of 2021, Epredia
will begin to commercialize the Paige solutions alongside existing
Epredia products in the United
States and major European Countries, further strengthening
its comprehensive digital pathology portfolio that already includes
the best-in-class CE-marked 3DHistech P1000 scanner*.
The Paige portfolio includes the Paige Platform, a comprehensive
imaging solution comprised of a fast, zero-footprint viewer,
storage capabilities and AI-based diagnostic software to help
pathologists review cases and support their overall workflow.
The FDA-cleared and CE-marked Paige Platform features
FullFocus™, an intuitive and responsive viewer for pathology scans
that supports primary diagnosis and their Data Management solution
for storage of pathology scans. The Paige Platform is designed to
be compatible with existing pathology solutions, including most
scanners, monitors, and laboratory information systems.
Paige's AI-based diagnostic software solutions are designed to
increase the number of cases that can be reviewed and with greater
confidence and accuracy. Currently Paige Prostate and Paige Breast
are CE-marked and available for clinical use outside of
the United States. Paige Prostate
RUO and Paige Breast RUO are research-use only solutions that are
available in the United
States.
"We are extremely excited to be entering into this partnership
with Paige to commercialize their highly innovative portfolio of
AI-based digital pathology solutions," explained John Marotta, President, Epredia and Chief
Executive Officer, PHC Holdings Corporation. "We believe that
digital pathology is a key part of cancer diagnostics of the future
that can greatly improve patient care. We see enormous potential in
the Paige portfolio and believe it perfectly complements our
existing portfolio. This deal gives us access to a highly
innovative portfolio of products that can enable us to deliver on
our mission of improving lives by enhancing cancer diagnostics for
patients."
"This commercial partnership with Epredia is an exciting step
for Paige and we are thrilled to be working with one of the leading
companies in anatomical pathology. Epredia's extensive global
commercial reach will support our efforts to expand our
geographical footprint," said Leo
Grady, Ph.D., Chief Executive Officer of Paige. "Our aim is
to transform the diagnostics space by offering a portfolio of
software applications that help optimize patient outcomes by
enabling pathologists to unlock insights from each sample and
return results to the clinician and patient more quickly. This
commercial agreement will help deliver our solution into the hands
of more pathologists across the world to help patients get the most
timely and effective care."
* Regulatory requirements for the 3DHistech P1000 scanner vary
by country, please consult with your commercial partner to confirm
the approved use of the scanner in your country.
Notes for Editors
About Epredia
Epredia is a global leader in the anatomical pathology field,
providing comprehensive solutions for precision cancer diagnostics
and tissue diagnostics. Powered by key brands, including Erie
Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan
Scientific, Epredia's portfolio includes microscope slides,
instruments and consumables. Epredia was established following the
acquisition of Thermo Fisher Scientific's Anatomical Pathology
business by PHC Holdings in 2019. Epredia has major sites in
the United States, the
United Kingdom, Germany, Switzerland and China with a total of around 1,200 employees.
Epredia is committed to achieving its mission to improve lives by
enhancing cancer diagnostics for patients around the world. For
further information on Epredia and its products, please visit
www.epredia.com.
About Paige
Paige was founded in 2017 by Thomas
Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering
Cancer Center (MSK). The company builds computational pathology
products designed so patients and their care teams can make
effective, more informed treatment decisions. With this new class
of AI-based technologies positioned to drive the future of
diagnostics, Paige created a platform to deliver this novel
technology to pathologists to transform their workflow and increase
diagnostic confidence and productivity. Paige's products deliver
insights to pathologists and oncologists so they can arrive
efficiently at more precise diagnoses for patients. Paige is the
first company to receive FDA breakthrough designation for
computational pathology products.
For additional information, please visit: https://www.paige.ai,
https://www.paigeplatform.com, Twitter, and LinkedIn.
Photo - https://mma.prnewswire.com/media/1458464/Epredia.jpg
Logo -
https://mma.prnewswire.com/media/1458465/Epredia_Logo.jpg